BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20605144)

  • 1. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.
    Imesch P; Fink D; Fedier A
    Fertil Steril; 2010 Dec; 94(7):2838-42. PubMed ID: 20605144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin.
    Imesch P; Samartzis EP; Schneider M; Fink D; Fedier A
    Fertil Steril; 2011 Apr; 95(5):1579-83. PubMed ID: 21295294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
    Vinodhkumar R; Song YS; Devaki T
    Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
    Chen J; Du C; Kang J; Wang J
    Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
    J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
    Rahim R; Strobl JS
    Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
    Kawano Y; Nasu K; Li H; Tsuno A; Abe W; Takai N; Narahara H
    Hum Reprod; 2011 Sep; 26(9):2486-98. PubMed ID: 21715447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
    Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
    Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
    Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
    Park H; Im JY; Kim J; Choi WS; Kim HS
    Int J Mol Med; 2008 Mar; 21(3):325-33. PubMed ID: 18288380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells.
    Imesch P; Samartzis EP; Dedes KJ; Fink D; Fedier A
    Fertil Steril; 2013 Sep; 100(3):770-6. PubMed ID: 23755949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.
    Savickiene J; Borutinskaite VV; Treigyte G; Magnusson KE; Navakauskiene R
    Eur J Pharmacol; 2006 Nov; 549(1-3):9-18. PubMed ID: 16978604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
    Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
    Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
    Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiment study of PHI on histone methylation and acetylation in Molt-4 cells].
    Huang YQ; Ma XD; Zhen RJ; Chiao JW; Liu DL
    Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):612-5. PubMed ID: 18246819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.